FIRDAPSE Q1 Revenue Reaches $98.9 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Reports Q1 revenue $149.4M, consensus $148.18M. FIRDAPSE Q1 2026 product revenue, net was $98.9 million, an 18.1% year-over-year increase, primarily driven by increases in sales volumes. AGAMREE Q1 2026 product revenue, net was $36.7 million, compared to product revenue, net of $22.0 million in Q1 2025. The results underscore continued sales volume growth and increasing prescriber engagement. FYCOMPA Q1 2026 product revenue, net was $13.8 million, a 61.3% year-over-year decrease following loss of exclusivity in 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CPRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CPRX
Wall Street analysts forecast CPRX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 31.290
Low
33.00
Averages
34.00
High
35.00
Current: 31.290
Low
33.00
Averages
34.00
High
35.00
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for patients living with rare and difficult-to-treat diseases. The Company markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating KalVista Pharmaceuticals (NASDAQ:KALV) for potential violations of federal securities laws related to its sale to Chiesi Group for $27.00 per share in cash, indicating possible breaches of fiduciary duties to shareholders.
- Shareholder Rights: The firm encourages KalVista shareholders to reach out to discuss their rights and options, highlighting the potential financial disadvantages they may face compared to ordinary shareholders in the proposed transaction.
- Other Companies Under Scrutiny: The investigation also includes Global Business Travel Group (NYSE:GBTG) selling for $9.50 per share to Long Lake Management, Modiv Industrial (NYSE:MDV) merging with Global Net Lease, and Catalyst Pharmaceuticals (NASDAQ:CPRX) selling for $31.50 per share to Angelini Pharma S.p.A.
- Legal Support Offered: Halper Sadeh LLC aims to seek increased consideration, additional disclosures, and other relief on behalf of shareholders, demonstrating a commitment to protecting shareholder interests and rights throughout these transactions.
See More
Multiple Company Sale Transactions and Shareholder Rights
- Transaction Overview: Catalyst Pharmaceuticals, Inc. is being sold to Angelini Pharma S.p.A. for $31.50 per share in cash, providing shareholders with immediate cash returns and enhancing investor confidence in the company's future value.
- UniFirst Sale: UniFirst Corporation is being sold to Cintas Corporation for $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, offering shareholders a flexible option that may attract various types of investors.
- RE/MAX Deal: RE/MAX Holdings, Inc. has a sale proposal that includes either 5.152 shares of the combined company or $13.80 in cash per share, aiming to provide shareholders with diversified exit strategies and enhance overall return potential.
- Legal Rights: Halper Sadeh LLC is seeking increased consideration and additional disclosures on behalf of shareholders, indicating a proactive stance in protecting shareholder rights, which may influence future corporate governance structures.
See More
Monteverde Law Firm Investigates Catalyst Pharmaceuticals Sale
- Shareholder Recovery: Monteverde & Associates has successfully recovered millions for shareholders, highlighting its recognition as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, which enhances its reputation in securities litigation.
- Transaction Investigation: The firm is currently investigating the sale of Catalyst Pharmaceuticals, Inc. to Angelini Pharma S.p.A., where shareholders are expected to receive $31.50 per share in cash, raising questions about the fairness of this deal in the market.
- Legal Service Transparency: Monteverde emphasizes that shareholders should inquire about a law firm's experience in class actions and past recovery successes when selecting legal representation, thereby ensuring they receive professional legal support and boosting shareholder confidence.
- Contact Information Provided: The firm offers free consultations, allowing shareholders to contact Juan Monteverde via email or phone for more information, demonstrating its commitment to client service and transparency.
See More
Catalyst Pharmaceuticals to Announce Q1 Earnings on May 11
- Earnings Announcement: Catalyst Pharmaceuticals is set to release its Q1 2023 earnings on May 11 after market close, with consensus EPS estimate at $0.64, reflecting a 5.9% year-over-year decline, while revenue is projected at $148.18 million, indicating a 5.1% increase, which could significantly impact investor sentiment.
- Historical Performance: Over the past two years, Catalyst has consistently beaten EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's stability in financial performance and its ability to manage market expectations effectively.
- Estimate Revision Trends: In the last three months, EPS estimates have seen three upward revisions and one downward revision, while revenue estimates have experienced three upward and two downward revisions, indicating fluctuations in analyst confidence regarding the company's future performance, which may influence investor decisions.
- Acquisition Interest: Catalyst's stock surged on reports of interest from Angelini Pharma for a $4.1 billion acquisition, which could present new strategic opportunities for the company while potentially impacting its future market positioning and financial health.
See More
Catalyst Pharmaceuticals Agrees to $4.1B Acquisition by Angelini Pharma
- Acquisition Agreement: Catalyst Pharmaceuticals has entered into a definitive agreement with Angelini Pharma for a $4.1 billion acquisition, expected to close in Q3 pending shareholder and regulatory approvals, highlighting the company's significant position in industry consolidation.
- Patent Litigation Resolution: The full settlement of FIRDAPSE patent litigation secures U.S. market exclusivity until January 2035, enhancing product market protection and boosting investor confidence in Catalyst's future.
- Strong Stock Performance: Catalyst's stock has risen 24.7% over the past month and 34.6% year-to-date, reflecting positive market sentiment regarding the acquisition and recognition of the company's growth potential.
- Investor Focus: As the deal progresses, investors should monitor the spread between the stock price and the implied deal value, as well as updates on shareholder and regulatory approvals, which will directly impact the transaction's completion and the company's strategic direction.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) regarding its sale to Angelini Pharma S.p.A. for $31.50 per share, as potential violations of shareholder rights may exist, prompting shareholders to understand their rights and options.
- Transaction Details: TruBridge, Inc. (NASDAQ:TBRG) is being sold to Inventurus Knowledge Solutions, Inc. for $26.25 per share in cash, with Halper Sadeh LLC urging shareholders to be aware of potential legal rights and compensation opportunities.
- Merger Impact: Following the proposed transaction, Modiv Industrial, Inc. (NYSE:MDV) shareholders are expected to own approximately 11% of the combined company, and Halper Sadeh LLC may seek increased compensation for shareholders.
- Legal Support: Halper Sadeh LLC represents investors globally, focusing on legal remedies for securities fraud and corporate misconduct, emphasizing its successful track record in implementing corporate reforms and recovering funds for defrauded investors.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Focus: Halper Sadeh LLC is investigating KalVista Pharmaceuticals (NASDAQ:KALV) for potential violations of federal securities laws related to its sale to Chiesi Group for $27.00 per share in cash, indicating possible breaches of fiduciary duties to shareholders.
- Shareholder Rights: The firm encourages KalVista shareholders to reach out to discuss their rights and options, highlighting the potential financial disadvantages they may face compared to ordinary shareholders in the proposed transaction.
- Other Companies Under Scrutiny: The investigation also includes Global Business Travel Group (NYSE:GBTG) selling for $9.50 per share to Long Lake Management, Modiv Industrial (NYSE:MDV) merging with Global Net Lease, and Catalyst Pharmaceuticals (NASDAQ:CPRX) selling for $31.50 per share to Angelini Pharma S.p.A.
- Legal Support Offered: Halper Sadeh LLC aims to seek increased consideration, additional disclosures, and other relief on behalf of shareholders, demonstrating a commitment to protecting shareholder interests and rights throughout these transactions.
See More
Multiple Company Sale Transactions and Shareholder Rights
- Transaction Overview: Catalyst Pharmaceuticals, Inc. is being sold to Angelini Pharma S.p.A. for $31.50 per share in cash, providing shareholders with immediate cash returns and enhancing investor confidence in the company's future value.
- UniFirst Sale: UniFirst Corporation is being sold to Cintas Corporation for $155.00 in cash and 0.7720 shares of Cintas stock per UniFirst share, offering shareholders a flexible option that may attract various types of investors.
- RE/MAX Deal: RE/MAX Holdings, Inc. has a sale proposal that includes either 5.152 shares of the combined company or $13.80 in cash per share, aiming to provide shareholders with diversified exit strategies and enhance overall return potential.
- Legal Rights: Halper Sadeh LLC is seeking increased consideration and additional disclosures on behalf of shareholders, indicating a proactive stance in protecting shareholder rights, which may influence future corporate governance structures.
See More
Monteverde Law Firm Investigates Catalyst Pharmaceuticals Sale
- Shareholder Recovery: Monteverde & Associates has successfully recovered millions for shareholders, highlighting its recognition as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, which enhances its reputation in securities litigation.
- Transaction Investigation: The firm is currently investigating the sale of Catalyst Pharmaceuticals, Inc. to Angelini Pharma S.p.A., where shareholders are expected to receive $31.50 per share in cash, raising questions about the fairness of this deal in the market.
- Legal Service Transparency: Monteverde emphasizes that shareholders should inquire about a law firm's experience in class actions and past recovery successes when selecting legal representation, thereby ensuring they receive professional legal support and boosting shareholder confidence.
- Contact Information Provided: The firm offers free consultations, allowing shareholders to contact Juan Monteverde via email or phone for more information, demonstrating its commitment to client service and transparency.
See More
Catalyst Pharmaceuticals to Announce Q1 Earnings on May 11
- Earnings Announcement: Catalyst Pharmaceuticals is set to release its Q1 2023 earnings on May 11 after market close, with consensus EPS estimate at $0.64, reflecting a 5.9% year-over-year decline, while revenue is projected at $148.18 million, indicating a 5.1% increase, which could significantly impact investor sentiment.
- Historical Performance: Over the past two years, Catalyst has consistently beaten EPS estimates 100% of the time and revenue estimates 88% of the time, showcasing the company's stability in financial performance and its ability to manage market expectations effectively.
- Estimate Revision Trends: In the last three months, EPS estimates have seen three upward revisions and one downward revision, while revenue estimates have experienced three upward and two downward revisions, indicating fluctuations in analyst confidence regarding the company's future performance, which may influence investor decisions.
- Acquisition Interest: Catalyst's stock surged on reports of interest from Angelini Pharma for a $4.1 billion acquisition, which could present new strategic opportunities for the company while potentially impacting its future market positioning and financial health.
See More
Catalyst Pharmaceuticals Agrees to $4.1B Acquisition by Angelini Pharma
- Acquisition Agreement: Catalyst Pharmaceuticals has entered into a definitive agreement with Angelini Pharma for a $4.1 billion acquisition, expected to close in Q3 pending shareholder and regulatory approvals, highlighting the company's significant position in industry consolidation.
- Patent Litigation Resolution: The full settlement of FIRDAPSE patent litigation secures U.S. market exclusivity until January 2035, enhancing product market protection and boosting investor confidence in Catalyst's future.
- Strong Stock Performance: Catalyst's stock has risen 24.7% over the past month and 34.6% year-to-date, reflecting positive market sentiment regarding the acquisition and recognition of the company's growth potential.
- Investor Focus: As the deal progresses, investors should monitor the spread between the stock price and the implied deal value, as well as updates on shareholder and regulatory approvals, which will directly impact the transaction's completion and the company's strategic direction.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Investigation Background: Halper Sadeh LLC is investigating Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) regarding its sale to Angelini Pharma S.p.A. for $31.50 per share, as potential violations of shareholder rights may exist, prompting shareholders to understand their rights and options.
- Transaction Details: TruBridge, Inc. (NASDAQ:TBRG) is being sold to Inventurus Knowledge Solutions, Inc. for $26.25 per share in cash, with Halper Sadeh LLC urging shareholders to be aware of potential legal rights and compensation opportunities.
- Merger Impact: Following the proposed transaction, Modiv Industrial, Inc. (NYSE:MDV) shareholders are expected to own approximately 11% of the combined company, and Halper Sadeh LLC may seek increased compensation for shareholders.
- Legal Support: Halper Sadeh LLC represents investors globally, focusing on legal remedies for securities fraud and corporate misconduct, emphasizing its successful track record in implementing corporate reforms and recovering funds for defrauded investors.
See More
